The benefits of radiofrequency catheter ablation (RFCA) for patients with atrial fibrillation (AF) significantly decrease with late recurrence (LR). We aimed to develop a scoring system to identify patients at high and low risk for LR following RFCA, based on a comprehensive evaluation of multiple risk factors for AF recurrence, including echocardiographic parameters. We studied 2,352 patients with AF undergoing first-time RFCA in a single institution. The LR-free survival rate up to 5 years was measured using a Kaplan-Meier analysis. The influence of clinical and echocardiographic parameters on LR was calculated with a Cox-regression analysis. Duration of AF ≥4 years (hazard ratio [HR] = 1.75; p < 0.001), non-paroxysmal AF (HR = 3.18; p < 0.001), and diabetes (HR = 1.34; p = 0.015) were associated with increased risk of LR. Left atrial (LA) diameter ≥45 mm (HR = 2.42; p < 0.001), E/e′ ≥ 10 (HR = 1.44; p < 0.001), dense SEC (HR = 3.30; p < 0.001), and decreased LA appendage flow velocity (≤40 cm/sec) (HR = 2.35; p < 0.001) were echocardiographic parameters associated with increased risk of LR following RFCA. The LR score based on the aforementioned risk factors could be used to predict LR (area under curve = 0.717) and to stratify the risk of LR (HR = 1.45 per 1 point increase in the score; p < 0.001). In conclusion, LR after RFCA is affected by multiple clinical and echocardiographic parameters. This study suggests that combining these multiple risk factors enables the identification of patients with AF at high or low risk for having arrhythmia recurrence.
Atrial fibrillation (AF) is a substantial global health burden, associated with impaired quality of life and increased risk of cardiovascular events1,2,3,4. Until Haissaguerre and his colleagues discovered that the pulmonary vein was the main trigger of AF and introduced radiofrequency catheter ablation (RFCA), AF was not considered a curable disease5. Twenty years after its introduction, RFCA is recommended for symptomatic and antiarrhythmic drug (AAD)-refractory paroxysmal AF6. Based on recent advancements in ablation results and techniques, RFCA is also a preferred choice for patients with symptomatic persistent AF6,7. With RFCA compared to AADs, a significant improvement in quality of life has been well documented in multiple studies and meta-analyses1,8,9,10,11. Recent studies have also suggested that RFCA reduces the risk of ischemic stroke in patients with AF12,13,14. Furthermore, all-cause mortality may be significantly improved in selected patients, according to the CASTLE-AF trial15.
The benefits of RFCA are closely associated with late recurrence (LR)1,16,17,18. However, the success rate of RFCA, especially in patients with non-paroxysmal AF, is still not optimal despite recent improvements7. The reported success rate of RFCA is between 40–80%, depending on patient characteristics, definition of LR, repeat procedures, and follow-up duration7,15,19. Large left atrium (LA) size, non-paroxysmal AF, and extensive late gadolinium enhancement of LA are well-established risk factors for LR following RFCA20,21,22,23,24. Duration of AF, age, body mass index (BMI), and various transthoracic and transesophageal echocardiographic parameters might also predict LR after undergoing RFCA. Furthermore, repeat procedures have proven its efficacy in reducing the rate of LR25,26. Various studies have reported individual risk factors for AF recurrence, but there has been no comprehensive analysis of multiple risk factors for LR. Hence, we sought to develop a scoring system to identify the true high- and low-risk groups for LR following their last RFCA procedure, based on a comprehensive evaluation of multiple risk factors for AF recurrence.
We analyzed consecutive patients with AF who underwent their first RFCA at Korea University Anam Hospital from June 1998 and May 2016. All patients who underwent RFCA in our institution were included, and there were no specific exclusion criteria. The current study was approved by the Institutional Review Board of Korea University Anam Hospital, which ensured appropriate ethical and bioethical conduct. Informed consent was waived since this was a retrospective study. All patient records and medical information were anonymized prior to analysis. The protocol of the current study was consistent with the ethical guidelines of the 2008 Helsinki Declaration.
Radiofrequency catheter ablation
Double trans-septal punctures were performed using a Brockenbrough needle and two SL1 sheaths. Three-dimensional mapping of LA was performed with either an EnSite NavX/Velocity (St. Jude Medical, St. Paul, MN, USA) or a CARTO (Biosense Webster, Irvine, CA, USA) system. Pulmonary vein isolation was performed for paroxysmal AF. After successful isolation of pulmonary veins, non-pulmonary vein trigger focus evaluation was performed by AF induction with rapid atrial pacing under isoproterenol infusion and subsequent direct current cardioversion. Additional non-pulmonary vein trigger ablation was performed if AF was initiated by trigger activity from non-pulmonary vein focus. End point of the procedure in paroxysmal AF patients was the absence of both pulmonary vein and non-pulmonary vein trigger focus. However, additional substrate modifications were performed in patients with paroxysmal AF if the operator considered non-inducibility more important than trigger focus elimination. Acquiring non-inducibility was the endpoint of the procedure for non-paroxysmal AF. Pulmonary vein isolation and additional complex fractionated atrial electrogram-guided or linear ablation were performed for non-paroxysmal AF, based on the operators’ discretion. Patients received routine anticoagulation treatment for 2–3 months after RFCA. Regular 12-lead surface electrocardiography and Holter evaluation was performed at 3, 6, 9, and 12 months after discharge. If patient complained of symptoms suggestive of recurrence but had no evidence of AF or atrial tachycardia in 12-lead surface electrocardiography or Holter evaluation, event recorder evaluation was performed.
Both transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) were performed before RFCA. All echocardiographic evaluations were performed by cardiologists dedicated in the field of cardiac imaging. During TTE, LA size, ejection fraction of left ventricle (LV), mitral valve inflow velocity (E), and mitral annular tissue velocity (E′) were measured. Multiple views (high esophageal 0°, 45°, 60°, and 120° views) were obtained during TEE evaluation. Emptying (forward), filling (backward), and the average flow velocity of the LA appendage (LAA) were measured. The presence of spontaneous echocontrast (SEC) and thrombus in LA or LAA were carefully evaluated. SEC was divided into grades of very mild (minimal echogenicity, only detectable transiently, or increasing gain setting required for the detection), mild (detectable without increasing gain setting), moderate (dense, swirling echogenic material; echogenic signal is dense in LAA compared to LA), or severe (dense, swirling echogenic material; echogenic signal is equivocal in LAA and LA). Dense SEC was defined as a composite of moderate and severe SEC.
In the current study, LR was defined as any atrial tachyarrhythmia lasting for more than 30 seconds in Holter monitoring or in the event recorder after the 3-month blanking period. Single strip (10 seconds) of 12-lead surface electrocardiography showing any type of atrial tachyarrhythmia was also defined as LR. The LR-free survival rate was calculated for both 5 years of follow-up and for the full follow-up period. Paroxysmal AF was defined as AF lasting for less than 7 days, and non-paroxysmal AF as AF lasting for more than 7 days. The duration of AF was calculated by the difference between the date of initial symptom onset (or first diagnosis of AF) and the RFCA index date. The LR score was calculated using the multiple risk factors for LR identified in the current study. The LR score was utilized to predict and stratify the risk of LR after the first and last RFCA procedures.
Continuous variables are described as means ± standard deviations, and were compared using a Student’s t-test. Categorical variables are presented as percentile values, and were compared with a chi-square test or Fisher’s exact test as appropriate. LR-free survival was measured by Kaplan-Meier survival curve analysis, and the difference between groups was assessed using a log-rank test. Cox regression analysis was performed to calculate the hazard ratio (HR) and its 95% confidence interval (CI) for each risk factor. Receiver operating characteristic (ROC) curve analysis with a calculation of the area under curve (AUC) was performed to evaluate the efficacy of the LR score to predict LR. Missing data were excluded from each analysis, and no imputation was performed. All significance tests were two-tailed, and p values equal or less than 0.05 were considered statistically significant. All statistical analyses were performed with SPSS version 21.0 (IBM, Armonk, NY, USA).
A total of 2,352 patients with AF who underwent RFCA for the first time were studied. The number of procedures was 2,997, with 546 patients having two procedures; 83, three; 12, four; 3, five; and 1, six procedures. The mean number of procedures per patient was 1.27, and the mean time interval between the first-time RFCA and the repeat procedure was 849 days. The baseline characteristics of the study population are summarized in Supplementary Table S1. The mean age was 55.4 ± 10.9 years, and 79.6% were male. Non-paroxysmal AF was diagnosed in 40.2% of the patients. The mean LA diameter and CHA2DS2-VASc score were 41.1 ± 6.0 mm and 1.3 ± 1.3 points, respectively. The total follow-up duration was 10,023 patient * years. During the follow-up, 969 (41.2%) and 613 (26.1%) patients experienced LR after their first and last RFCA procedures, respectively.
Risk factors for LR after last RFCA
Baseline clinical and echocardiographic characteristics were compared between patients with and without LR after their last RFCA (Table 1). Patients who experienced LR following the last RFCA were older (54.7 ± 10.9 vs. 57.3 ± 10.8 years old; p < 0.001) and had a high BMI (24.8 ± 2.9 vs. 25.2 ± 3.3 kg/m2; p = 0.014); long AF duration (4.4 ± 4.3 vs. 5.9 ± 5.4 years; p < 0.001); high CHA2DS2-VASc score (1.2 ± 1.2 vs. 1.6 ± 1.4; p < 0.001); large LA (40.3 ± 5.6 vs. 43.5 ± 6.3 mm; p < 0.001); low LV ejection fraction (55.1 ± 5.9 vs. 54.1 ± 6.7%; p = 0.001); high E/E′ (8.7 ± 3.3 vs. 9.6 ± 5.6; p = 0.001); and low average LAA flow velocity (51.3 ± 20.7 vs. 41.0 ± 19.9 cm/sec; p < 0.001). They also had a higher proportion of female sex (19.4% vs. 23.2%; p = 0.049), non-paroxysmal AF (32.9% vs. 60.7%; p < 0.001), SEC (16.5% vs. 35.3%; p < 0.001), and dense SEC (2.0% vs. 8.3%; p < 0.001). Among these parameters, BMI and sex status were not associated with an increased risk of LR in Cox-regression or ROC curve analyses, and were not included in the subsequent analysis. Among individual component of CHA2DS2-VASc score, diabetes, heart failure, and previous history of stroke or TIA were associated with increased risk of LR. However, heart failure and previous history of stroke or TIA were not included in the subsequent analysis since LV ejection fraction, LAA flow velocity, and presence of dense SEC were included instead.
Patients with AF duration ≥4 years (73.3% vs. 58.3%, log-rank p < 0.001; HR = 1.75, 95% CI = 1.47–2.07, p < 0.001; Fig. 1a), age ≥60 years (69.0% vs. 60.1%, log-rank p = 0.001; HR = 1.31, 95% CI = 1.11–1.55, p = 0.001; Fig. 1b), non-paroxysmal AF (77.7% vs. 47.0%, log-rank p < 0.001; HR = 3.18, 95% CI = 2.67–3.78, p < 0.001; Fig. 1c), and diabetes (66.1% vs. 60.8%, log-rank p = 0.015; HR = 1.34, 95% CI = 1.06–1.70, p = 0.015; Fig. 1d) showed a significantly lower rate of LR-free survival for up to 5 years following the last RFCA. Kaplan-Meier curves for the full follow-up period are depicted in Supplementary Fig. S1.
LA diameter ≥45 mm (71.5% vs. 47.0%, log-rank p < 0.001; HR = 2.42, 95% CI = 2.05–2.87, p < 0.001; Fig. 2a), LV ejection fraction < 50% (66.7% vs. 57.4%, log-rank p = 0.002; HR = 1.38, 95% CI = 1.12–1.70, p = 0.002; Fig. 2b), and E/E′ ≥ 10 (69.7% vs. 61.2%, log-rank p < 0.001; HR = 1.44, 95% CI = 1.19–1.74, p < 0.001; Fig. 2c) were also associated with a significantly increased risk of AF recurrence for up to 5 years after the last RFCA procedure. The presence of SEC (70.7% vs. 44.6%, log-rank p < 0.001; HR = 2.24, 95% CI = 1.87–2.68, p < 0.001; Fig. 3a), dense SEC (66.6% vs. 24.2%, log-rank p < 0.001; HR = 3.30, 95% CI = 2.43–4.48, p < 0.001; Fig. 3b), and decreased average LAA flow velocity (≤40 cm/sec) (72.5% vs. 49.7%, log-rank p < 0.001; HR = 2.35, 95% CI = 1.97–2.79, p < 0.001; Fig. 3c) found during TEE evaluation showed strong associations with LR for up to 5 years after the last RFCA. Kaplan-Meier curves of the full follow-up duration for TTE and TEE risk factors are presented in Supplementary Figs S2 and S3, respectively.
We created the LR score to identify patients who are at high or low risk for LR after their last RFCA. Multivariate Cox regression analysis was performed for individual risk factors identified in the previous analysis (Figs 1–3) and the results are summarized in Table 2. Based on the multivariate analysis, factors with p value less than 0.1 was selected to be included in the LR scoring system.
Each risk factor was assigned points as follows: one point for AF duration ≥4 years, LA diameter ≥45 mm, E/e′ ≥ 10, LAA flow velocity ≤40 cm/sec, presence of dense SEC, history of diabetes; two points for non-paroxysmal AF. The risk of LR differed significantly according to LR score (HR = 1.45 per 1 point increase, 95% CI = 1.38–1.53; p < 0.001; Fig. 4a). ROC curve analysis also revealed that the LR score could predict LR after the last RFCA (AUC = 0.717; 95% CI = 0.697–0.738; p < 0.001; Fig. 4b). Patients with LR score 0 showed excellent results, with 89.1% of the patients maintaining sinus rhythm for up to 5 years of follow up. However, patients with LR score ≥5 showed poor prognosis, with only 32.6% of the patients having LR-free survival through 5 years of follow up. Late recurrence following first RFCA can also be predicted by LR score (HR = 1.34 per 1 point increase, 95% CI = 1.28–1.39, p < 0.001; AUC = 0.687, p < 0.001; Supplementary Fig. S4).
The CHA2DS2-VASc score also had predictive value for LR after last RFCA (HR = 1.17 per 1 point increase; 95% CI = 1.11–1.25; p < 0.001; Supplementary Fig. S5a). However, the LR score system significantly outperformed the CHA2DS2-VASc score (AUC = 0.717 vs. 0.571; p < 0.001; Supplementary Fig. S5b).
LR after first and last RFCA
Undergoing repeat procedures was associated with significantly improved LR-free survival (65.6% vs. 51.2%, log-rank p < 0.001; HR = 0.58, 95% CI = 0.52–0.65, p < 0.001; Fig. 5a). The relationship of improved outcome with undergoing repeated procedures was maintained in both paroxysmal AF (77.7% vs. 64.0%, log-rank p < 0.001; HR = 0.52, 95% CI = 0.44–0.62, p < 0.001; Fig. 5b) and non-paroxysmal AF (47.0% vs. 32.4%, log-rank p < 0.001; HR = 0.61, 95% CI = 0.53–0.70, p < 0.001; Fig. 5c).
In the current study, multiple clinical and echocardiographic parameters were identified as risk factors for LR following RFCA. The clinical risk factors were type of AF, duration of AF, and diabetes. Left atrial diameter, E/e′, presence of dense SEC, and decreased LAA flow velocity were echocardiographic risk factors for LR following RFCA. The LR score, which was created based on the aforementioned risk factors, could be used to predict LR, with an AUC of 0.717. Patient groups based on LR score had significantly different risks for experiencing LR following RFCA. In current clinical practice, the type of AF and diameter of LA are usually taken into account when predicting the success rate of RFCA in patients with AF. However, our analysis revealed that recurrence after RFCA is affected by multiple other risk factors as well. A significant number of patients (91%) underwent both TTE and TEE evaluation, and we were able to examine multiple echocardiographic parameters that reflect the hemodynamics of LA, LAA, and LV.
Clinical risk factors
In accordance with previous studies, we found that longer duration of AF (≥4 years) and history of diabetes mellitus were independently associated with a significantly increased risk of LR following the last RFCA. Non-paroxysmal AF was associated with a 3-fold increased risk of LR following the last RFCA. The CHA2DS2-VASc score system, which is composed of clinical factors, was able to predict LR after RFCA. However, the LR score system which is composed of both clinical and echocardiographic parameters, was significantly superior to the CHA2DS2-VASc score system for the prediction of LR.
Previous studies have demonstrated that AF is a progressive disease, and a substantial number of paroxysmal AF events eventually progress to non-paroxysmal AF as time goes on27,28. Progressive structural remodeling of LA is probably the underlying mechanism28. Therefore, it is not surprising that a longer AF duration is associated with a higher recurrence rate. The benefit of performing early RFCA in patients with paroxysmal AF before LA remodeling and conversion to non-paroxysmal AF should be tested in future clinical trials. Previous studies identified female sex as a risk factor for LR after RFCA7,29,30. However, in our analysis, female sex was not associated with increased risk of LR following the last RFCA in a Cox regression analysis. The role of sex status as a risk factor for recurrence after RFCA needs to be clarified in future studies.
Echocardiographic risk factors
LA diameter is traditionally regarded as a risk factor for recurrence after RFCA. Our study also showed that large LA diameter was associated with a significantly increased risk of LR following RFCA. In addition, LV ejection fraction and E/e′ were related to an increased risk of LR after RFCA. Cardiac chambers are not independent structures, and both LV systolic and diastolic function affect the LA. Decreased LV function can increase LA filling pressure and eventually dilate the LA. An extreme result of diastolic dysfunction is hypertrophic cardiomyopathy, which is associated with both AF and ischemic stroke. Therefore, post-procedural care should not only focus on LA but also on LV.
We also identified TEE parameters that were associated with an increased risk of LR following the last RFCA. Previous studies focused on LA diameter as a risk factor for recurrence, but TEE parameters such as the presence of dense SEC and decreased flow velocity of the LAA also deserve further attention. The presence of SEC is generally considered to be a consequence of impaired blood flow, atrial fibrosis, and decreased contraction of the LA and the LAA31. Therefore, the presence of SEC in the LA and the LAA can be regarded as a surrogate marker for decreased LA and LAA hemodynamic function. Left atrial remodeling due to AF progression will result in more fibrosis in the LA, which will in turn decrease its contractility and will eventually result in development of SEC31,32. Therefore, SEC can be considered as a common final result of LA remodeling, fibrosis, dilation, and decreased hemodynamic function. In our study, SEC and dense SEC were associated with a 2.24-fold and a 3.30-fold increased risk of LR following the last RFCA, respectively. Decreased LAA flow velocity, which reflects decreased hemodynamic function of the LA and the LAA, was also associated with a 2.35-fold increased risk of LR. Physicians should consider these unfavorable TEE findings when deciding whether to perform RFCA.
Identification of patients at low and high risk of LR following RFCA
The risk of LR differed significantly according to LR score with 45% increased risk of recurrence for every 1 point increase in LR score. The low-risk group with LR score 0 showed excellent clinical results, with 89.1% of them having no arrhythmia recurrence up to 5 years of follow up. These patients have the highest chance to maintain sinus rhythm after RFCA, and electrophysiologists should discuss these findings with their patients during decision making. Repeat procedures were shown to be effective in improving the LR-free survival rate. Patients with either paroxysmal or non-paroxysmal AF derived substantial benefit from repeat procedures and therefore, repeat procedures may be recommended to patients who experienced LR, regardless of AF type. Patients with high LR score (≥5), only 32.6% maintained sinus rhythm despite repeat procedures during 5 years of follow up. Patients with a high LR score can be informed that the success rate of RFCA, including repeat procedures, might not fulfill their expectations.
The current study has several shortcomings. First, this was a retrospective analysis. Second, magnetic resonance image data were not available from a substantial number of patients, and therefore were not included in the analysis. Third, we could not retrieve the rhythm status during TEE evaluation which might further increase the predictive value of LAA flow velocity. Integration of late gadolinium enhancement data into the scoring system might further improve the prognostic value of the LR score.
This study demonstrated that the risk factors for LR following the last RFCA were longer duration of AF, non-paroxysmal AF, diabetes, large LA diameter, high E/e′, presence of dense SEC, and decreased flow velocity in the LAA. The LR scoring system based on the aforementioned risk factors can be used to predict future risk of arrhythmia recurrence following RFCA.
All data generated or analysed during this study are included in this published article (and its Supplementary Information Files).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Kim, Y. G., Shim, J., Choi, J. I. & Kim, Y. H. Radiofrequency Catheter Ablation Improves the Quality of Life Measured with a Short Form-36 Questionnaire in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis. PLoS One 11, e0163755 (2016).
Corley, S. D. et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109, 1509–1513 (2004).
Petersen, P. Thromboembolic complications in atrial fibrillation. Stroke 21, 4–13 (1990).
Lip, G. Y., Tse, H. F. & Lane, D. A. Atrial fibrillation. Lancet 379, 648–661 (2012).
Haissaguerre, M. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339, 659–666 (1998).
January, C. T. et al. AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130, 2071–2104 (2014).
Pallisgaard, J. L. et al. Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study. Eur Heart J 39, 442–449 (2018).
Wilber, D. J. et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 303, 333–340 (2010).
Morillo, C. A. et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 311, 692–700 (2014).
Wazni, O. M. et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 293, 2634–2640 (2005).
Jais, P. et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 118, 2498–2505 (2008).
Saliba, W. et al. Catheter ablation of atrial fibrillation is associated with reduced risk of stroke and mortality: A propensity score-matched analysis. Heart Rhythm 14, 635–642 (2017).
Friberg, L., Tabrizi, F. & Englund, A. Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries. Eur Heart J 37, 2478–2487 (2016).
Karasoy, D. et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. Eur Heart J 36, 307–314a (2015).
Marrouche, N. F. et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med 378, 417–427 (2018).
Ghanbari, H. et al. Mortality and cerebrovascular events after radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 11, 1503–1511 (2014).
Themistoclakis, S. et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 55, 735–743 (2010).
Bunch, T. J. et al. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol 22, 839–845 (2011).
Verma, A. et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 372, 1812–1822 (2015).
Marsan, N. A. et al. Comparison of left atrial volumes and function by real-time three-dimensional echocardiography in patients having catheter ablation for atrial fibrillation with persistence of sinus rhythm versus recurrent atrial fibrillation three months later. Am J Cardiol 102, 847–853 (2008).
Helms, A. S. et al. Relation of left atrial volume from three-dimensional computed tomography to atrial fibrillation recurrence following ablation. Am J Cardiol 103, 989–993 (2009).
Marrouche, N. F. et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 311, 498–506 (2014).
Wynn, G. J. et al. Efficacy of catheter ablation for persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized and nonrandomized controlled trials. Circ Arrhythm Electrophysiol 7, 841–852 (2014).
Balk, E. M. et al. Predictors of atrial fibrillation recurrence after radiofrequency catheter ablation: a systematic review. J Cardiovasc Electrophysiol 21, 1208–1216 (2010).
Winkle, R. A., Mead, R. H., Engel, G. & Patrawala, R. A. Long-term results of atrial fibrillation ablation: the importance of all initial ablation failures undergoing a repeat ablation. Am Heart J 162, 193–200 (2011).
Bhargava, M. et al. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study. Heart Rhythm 6, 1403–1412 (2009).
Padfield, G. J. et al. Progression of paroxysmal to persistent atrial fibrillation: 10-year follow-up in the Canadian Registry of Atrial Fibrillation. Heart Rhythm 14, 801–807 (2017).
Walters, T. E. et al. Progression of atrial remodeling in patients with high-burden atrial fibrillation: Implications for early ablative intervention. Heart Rhythm 13, 331–339 (2016).
Sultan, A. et al. Predictors of Atrial Fibrillation Recurrence after Catheter Ablation: Data from the German Ablation Registry. Sci Rep 7, 16678 (2017).
Schreiber, D. et al. Five-year follow-up after catheter ablation of persistent atrial fibrillation using the stepwise approach and prognostic factors for success. Circ Arrhythm Electrophysiol 8, 308–317 (2015).
Kim, Y. G. et al. Non-vitamin K antagonist oral anticoagulants versus warfarin for the prevention of spontaneous echo-contrast and thrombus in patients with atrial fibrillation or flutter undergoing cardioversion: A trans-esophageal echocardiography study. PLoS One 13, e0191648 (2018).
Choi, J. I. et al. Effects of Angiotensin-II Receptor Blocker on Inhibition of Thrombogenicity in a Canine Atrial Fibrillation Model. Korean Circ J 46, 335–342 (2016).
This work was supported by a Korea University Grant (J.-I.C.) and a grant from Korea University Anam Hospital, Seoul, Republic of Korea (J.-I.C.), and in part by grants from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (NRF-2015R1D1A1A02061859 to J.-I.C.) and the Ministry of Science, ICT, & Future Planning (NRF-2012R1A1A1013260 to J.-I.C.).